Home » Newsletters » BioWorld Science

BioWorld Science

May 25, 2006

View Archived Issues

Regeneron reports progress across key programs in first quarter

CPG-10101 improves responses in relapsed hepatitis C treatment responders

In vitro data show activity of AR-709 against multidrug resistant S. pneumoniae

Phase I study of TNX-650 begins dosing

AVANT study to resume enrollment

QR-435 to be studied for ocular herpes in animals

Immtech enters expanded funding agreements for pafuramidine maleate

Updated survival data from phase I study of DCVax-Brain in GBM patients

Screening begins in phase III trial of NRP-104 for adult ADHD

Two new phase II studies for ZK-EPO in breast and ovarian cancers

FDA clears ALK-Abello to begin phase I study of ragweed allergy vaccine tablet

Avanir to acquire Alamo Pharmaceuticals

Novartis involved in new public-private partnership for malaria

Enrollment open in phase II study of TroVax for prostate cancer

Teriparatide studied in new trial for osteogenesis imperfecta

SB-462795 increases bone strength in male monkeys

Once-daily carvedilol effective in patients with hypertension

Randomized trials reveal efficacy of valsartan and valsartan/amlodipine in hypertension

Herceptin approved in Europe for early use in HER2-positive breast cancer

FDA approval for Ionsys transdermal analgesic system

Equasym for ADHD completes European mutual recognition procedure

Novel treatment strategies for cancer covered in recent patents

Chemokine CXCR4 antagonists reported by Merck & Co.

Recent Kotobuki patent describes new agents for hyperphosphatemia

Novel motilin receptor agonist shows in vivo efficacy as prokinetic agent

MD-1100's active metabolite characterized in vitro and in vivo by Microbia

Selective adenosine A2A receptors with potential in CNS disorders developed by Schering-Plough

Curcumin derivative shows potential for the treatment of colon cancer by blocking EGFR signaling

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...